Organogenesis Holdings (ORGO) Receivables (2017 - 2026)

Organogenesis Holdings' Receivables history runs 10 years deep, the most recent figure standing at $131.3 million for Q1 2026.

• On a quarterly basis, Receivables rose 16.8% year-over-year to $131.3 million in Q1 2026; TTM through Mar 2026 was $131.3 million, a 16.8% increase from a year earlier, with the FY2025 full-year figure at $246.5 million, up 106.35% from the prior year.
• Receivables eased to $131.3 million in Q1 2026 per ORGO's latest filing, from $246.5 million in the prior quarter.
• Across five years, Receivables topped out at $246.5 million in Q4 2025 and bottomed at $79.5 million in Q1 2022.
• The 5-year median for Receivables is $103.6 million (2024), against an average of $116.2 million.
• Across the five-year window, Receivables declined 0.66% in 2023 and soared 124.34% in 2025, its largest moves.
• Year by year, Receivables stood at $89.4 million in 2022, then declined by 0.66% to $88.9 million in 2023, then advanced by 23.64% to $109.9 million in 2024, then jumped by 124.34% to $246.5 million in 2025, then tumbled by 46.74% to $131.3 million in 2026.
• Per Business Quant, the three latest ORGO Receivables figures stand at $131.3 million (Q1 2026), $246.5 million (Q4 2025), and $182.2 million (Q3 2025).